Tryp Therapeutics is a company leading the pharmaceutical development of psychedelics-assisted therapies, proving to offer treatment options in areas of high unmet medical need that extend beyond depression and PTSD. The company is providing investors an opportunity to get in on the growth before it booms.
Tryp Therapeutics (OTC: TRYPF, CSE:TRYP) is an American pharmaceutical company emerging as one of the leaders in the pharmaceutical development of psychedelics-assisted therapies with a focus on chronic pain and eating disorders. With extensive research demonstrating the benefits of psilocybin in treating mental health issues, Tryp is elaborating on this, developing compounds designed to address neurological disorders through the therapeutic dosing of synthetic psilocybin.
About Tryp Therapeutics
Focused on identifying and developing clinical-stage compounds for the treatment of orphan diseases and other diseases with high unmet medical needs, Tryp is an industry leading pharmaceutical company taking a unique approach in the booming psychedelic industry.
The company brings together a highly experienced leadership team from biotechnology and pharmaceutical sectors with a history of taking therapeutics through the FDA’s regulatory process to commercialization, managing publicly traded companies, and building profitable biotech companies.
Greg McKee, Tryp’s CEO, brings to his role over 20 years of experience leading biotech companies and supporting early-stage pharmaceutical start-ups. Co-founders Bill Gardner M.D. and Jim Kuo M.D. are both seasoned executives in the biotech space and have shaped the company to offer the solutions to issues that have long been overlooked. President & Chief Science Officer (CSO), Dr. James Gilligan, has spent over 35 years in the life science industry, co-founding many successful biopharmaceutical and biotech companies.
With an equally impressive Scientific Advisory Board led by world-renowned psychedelic expert and researcher, Robin Carhart-Harris, the team surrounding Tryp Therapeutics is world-class, optimally positioned to take the company and their research to new heights.
The history of psilocybin and psychedelics
Robert Gordon Wasson, a world renowned mycologist, is recognized as the individual to first share the psychedelic experience of psilocybin with the masses when he recounted his findings in Life Magazine in 1957. Sharing that, “The mushrooms were of a species with hallucinogenic powers; that is, they cause the eater to see visions. We chewed and swallowed these acrid mushrooms, saw visions, and emerged from the experience awestruck. [We] were the first white men in recorded history to eat the divine mushrooms, which for centuries have been a secret of certain Indian peoples.”
Wasson’s discovery sparked a surge of interest in the substance, spurring psychedelic research that persisted throughout the 50s and 60s. The results from these studies were published in hundreds of academic journals, however, most of this research was not taken seriously due to the small size of the studies and inconsistency with current research standards.
As magic mushrooms grew in popularity, they became inextricably tied to the hippie movement throughout the 60s. For many years, psychedelics were mostly associated with the counterculture and antiwar movements. Manufacturing and distributing uncontrolled substances on the black market as well as “bad trips” and catastrophes from recreational use led to widespread negative publicity for psychedelics.
In 1970, research on therapeutic uses of psychedelics came to a halt when Nixon introduced the Controlled Substances Act. Substances including MDMA, LSD, DMT, mescaline, cannabis, and psilocybin were categorized as Schedule I restricted drugs.
The psychedelic renaissance
The steady resurgence of human psychedelic research began in the early 1990s when the FDA started approving careful studies of psychoactive substances for the first time in decades. Founded in 1993, The Heffter Research Institute, focused mainly on therapeutic uses for psilocybin while the Multidisciplinary Association for Psychedelic Studies (MAPS), a non-profit organization founded in 1986, studied a wide range of hallucinogens. Notably, the psychotherapeutic potential of MDMA, LSD, ibogaine, ayahuasca, and medical marijuana.
In the past few years, research has dramatically ramped up as psychedelics have been gaining mainstream and government acceptance and decriminalization. Researchers from Johns Hopkins reported promising results using psilocybin for depression, nicotine addiction, and cancer-related distress.
“Psychedelics break the paradigm in how traditional small molecule drugs, biologicals, and vaccines are known to work,” shared Greg McKee. “In particular, psilocybin’s pharmaceuticals’ effects have been shown in multiple clinical studies to: 1) extend far beyond the half-life of the drug so only one dose every few weeks or months should be necessary, 2) have shown therapeutic responses in the majority of patients dosed with the drug, and 3) demonstrates efficacy in patients who have been resistant to all other therapies. For these reasons, psychedelic drug candidates represent the most exciting new class of drugs in psychiatry.”
These discoveries give even more credence to psilocybin’s effectiveness as a viable treatment for multiple mental health disorders.
More than just mental health
Unlike most companies in the psychedelic space, Tryp’s intention is not to simply create a treatment option that will best its competitors. Rather, the burgeoning life sciences company is going beyond the use of psilocybin for mental health issues.
With two active development programs in its pipeline, Tryp is well positioned to be the leader in alternative treatments for fibromyalgia and over-eating disorders.
“Tryp chose to focus on chronic pain and eating disorders because it wanted to address the major problems impacting our society,” informed McKee. “Many of us have a family member with these problems or know someone who does. They are disorders that disrupt anything approaching normalcy.”
Tryp’s Psilocybin-for-Neuropsychiatric Disorders (PFN™) Program is focused on psilocybin drug therapies for the treatment of certain neuropsychiatric disorders. Tryp’s lead PFN™ Program drug candidate is TRP-8802. It possesses distinct advantages over therapies currently on the market, including: natural blood-brain barrier penetration, enhanced safety and toxicity profiles, reduced risk of abuse, and reduced risk of addiction.
Tryp seeks to deliver therapies with improved efficacy, cost-effectiveness, and adherence, while eliminating side effects and strain from the healthcare system.
The psychedelic space is an early opportunity for investors
As the FDA continues to approve and fast-track several clinical research trials, the burgeoning psychedelics space presents an attractive opportunity for investors to capitalize on this new class of therapeutics, which employ the use of psilocybin as the key ingredient.
Many investors are reminded of what happened with the legal marijuana boom nearly a decade ago. However, more akin to the biotech sector, the psychedelic industry has moved forward with a heavy amount of peer-reviewed academic studies, while the cannabis industry has largely focused strategically on recreational use over therapeutics.
Oncology is the leading established pharmaceutical therapeutic category estimated to grow to 30% of all drug sales by 2024, which translates to approximately US $200 billion. Due in large part to the investments in scientific progress, the psychedelic pharma space appears to be a very good opportunity for investors.
For those who are anticipating new therapies for conditions that do not have good treatments in place, psychedelics – and more specifically, psilocybin – provide a hopeful shift in societal perceptions and mindset toward a new future of possibilities in psychedelic medicine.